Form 4: Travere Therapeutics CLO Executes Stock Transactions

Chief Legal Officer Elizabeth E. Reed reported the exercise of stock options and the vesting of performance-based restricted stock units.

Summary

• Elizabeth E. Reed, Chief Legal Officer and General Counsel of Travere Therapeutics, Inc., exercised options for 20,000 shares at $17.96 per share.
• The reporting person sold 20,000 shares at $45.00 per share pursuant to a Rule 10b5-1 trading plan.
• 4,250 performance-based restricted stock units (PSUs) vested following the achievement of cumulative FILSPARI net revenue performance criteria.
• Additional shares were sold to cover tax withholding obligations related to the vesting of PSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing reflecting standard executive equity management and the achievement of pre-defined performance milestones.

Positives

• Achievement of performance criteria related to cumulative FILSPARI net revenue, triggering the vesting of PSUs.
• Successful exercise of vested employee stock options.

Negatives

• Reduction in direct beneficial ownership of common stock following the sale of shares.

Risks

• Future vesting of remaining PSUs is contingent upon the reporting person's continuous service to the issuer.

Future Outlook

The company expects an additional 25% of the granted PSUs to vest on January 31, 2027, contingent upon the reporting person's continuous service.

Management Comments

• The vesting of PSUs was confirmed following the release of financial results for the quarter ended March 31, 2026, confirming the achievement of cumulative FILSPARI net revenue performance criteria.

Industry Context

StockSavvy.ai notes that the achievement of revenue-based performance milestones for FILSPARI highlights the ongoing commercial ramp-up of Travere's lead asset, which is a critical indicator of health for mid-cap biopharmaceutical firms.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is standard practice for corporate executives to mitigate legal risk during equity liquidation.
• Performance-based vesting criteria tied to specific product revenue milestones is a common incentive structure in the biotechnology sector to align management with commercial success.

Stakeholder Impact

• Shareholders may view the achievement of revenue milestones as a positive indicator of product adoption.

Next Steps

• Vesting of remaining 25% of PSUs on January 31, 2027.

Key Dates

Keywords

Travere Therapeutics, TVTX, Form 4, Insider Trading, FILSPARI, Equity Compensation